使用 CRISPR/Cas9 技术生成抗 CD5 CAR 敲入的人诱导多能干细胞系
Generation of an anti-CD5 CAR knock-in human induced pluripotent stem cell line using CRISPR/Cas9 technology.
肿瘤细胞治疗研究
MODALITY HUB
FOR TREATMENT
现在就能报名的(招募中)排在最前,共 0 项。同一状态内中国中心优先。信息来自 ClinicalTrials.gov、CDE 与 ChiCTR 公开登记。能否入组、费用与可及性,以登记原文和主治医生判断为准。
FOR RESEARCH
Generation of an anti-CD5 CAR knock-in human induced pluripotent stem cell line using CRISPR/Cas9 technology.
T cells expressing CD5/CD7 bispecific chimeric antigen receptors with fully human heavy-chain-only domains mitigate tumor antigen escape.
MEMBER ACCOUNT
登录成功会直接打开下一页。